Pharmacokinetics, pharmacodynamics and tolerability of single escalating doses of SAR 302503 in male volunteers

Trial Profile

Pharmacokinetics, pharmacodynamics and tolerability of single escalating doses of SAR 302503 in male volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Oct 2013

At a glance

  • Drugs Fedratinib (Primary)
  • Indications Myelofibrosis
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Sanofi
  • Most Recent Events

    • 25 Apr 2013 New trial record
    • 10 Apr 2013 Results presented at the 104th Annual Meeting of the American Association for Cancer Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top